OBJECTIVES: To develop and provide initial validation for amultivariate, claims-based prediction model for disability status (DS), a proxymeasure of performance status (PS), among older adults. The model was designed to augment information on health status at the point of cancer diagnosis in studies using insurance claims to examine cancer treatment and outcomes. MATERIALS AND METHODS: We used data from the 2001–2005 Medicare Current Beneficiary Survey (MCBS), with observations randomly split into estimation and validation subsamples. We developed an algorithm linking self-reported functional status measures to a DS scale, a proxy for the Eastern Cooperative Oncology Group (ECOG) PS scale. The DS measure was dichotomized to focus on good [ECOG 0–2] versus poor [ECOG 3–4] PS. We identified potential claims-based predictors, and estimated multivariate logistic regression models, with poor DS as the dependent measure, using a stepwise approach to select the optimal model. Construct validity was tested by determining whether the predicted DS measure generated by the model was a significant predictor of survival within a validation sample from the MCBS. RESULTS AND CONCLUSION: One-tenth of the beneficiaries met the definition for poor DS. The base model yielded high sensitivity (0.79) and specificity (0.92); positive predictive value=48.3% and negative predictive value=97.8%, c-statistic=0.92 and good model calibration. Adjusted poor claims-based DS was associated with an increased hazard of death (HR=3.53, 95% CI 3.18, 3.92). The ability to assess DS should improve covariate control and reduce indication bias in observational studies of cancer treatment and outcomes based on insurance claims.
OBJECTIVES: To develop and provide initial validation for amultivariate, claims-based prediction model for disability status (DS), a proxymeasure of performance status (PS), among older adults. The model was designed to augment information on health status at the point of cancer diagnosis in studies using insurance claims to examine cancer treatment and outcomes. MATERIALS AND METHODS: We used data from the 2001–2005 Medicare Current Beneficiary Survey (MCBS), with observations randomly split into estimation and validation subsamples. We developed an algorithm linking self-reported functional status measures to a DS scale, a proxy for the Eastern Cooperative Oncology Group (ECOG) PS scale. The DS measure was dichotomized to focus on good [ECOG 0–2] versus poor [ECOG 3–4] PS. We identified potential claims-based predictors, and estimated multivariate logistic regression models, with poor DS as the dependent measure, using a stepwise approach to select the optimal model. Construct validity was tested by determining whether the predicted DS measure generated by the model was a significant predictor of survival within a validation sample from the MCBS. RESULTS AND CONCLUSION: One-tenth of the beneficiaries met the definition for poor DS. The base model yielded high sensitivity (0.79) and specificity (0.92); positive predictive value=48.3% and negative predictive value=97.8%, c-statistic=0.92 and good model calibration. Adjusted poor claims-based DS was associated with an increased hazard of death (HR=3.53, 95% CI 3.18, 3.92). The ability to assess DS should improve covariate control and reduce indication bias in observational studies of cancer treatment and outcomes based on insurance claims.
Authors: Amer M Zeidan; Franklin Hendrick; Erika Friedmann; Maria R Baer; Steven D Gore; Medha Sasane; Carole Paley; Amy J Davidoff Journal: J Comp Eff Res Date: 2015-08 Impact factor: 1.744
Authors: Carmen C Cuthbertson; Anna Kucharska-Newton; Keturah R Faurot; Til Stürmer; Michele Jonsson Funk; Priya Palta; B Gwen Windham; Sydney Thai; Jennifer L Lund Journal: Epidemiology Date: 2018-07 Impact factor: 4.822
Authors: Scott F Huntington; Jessica R Hoag; Weiwei Zhu; Rong Wang; Amer M Zeidan; Smith Giri; Nikolai A Podoltsev; Steven D Gore; Xiaomei Ma; Cary P Gross; Amy J Davidoff Journal: Cancer Date: 2018-09-14 Impact factor: 6.860
Authors: Amy J Davidoff; Xin Hu; Jan Philipp Bewersdorf; Rong Wang; Nikolai A Podoltsev; Scott F Huntington; Steven D Gore; Xiaomei Ma; Amer M Zeidan Journal: Leuk Lymphoma Date: 2019-12-26
Authors: Keturah R Faurot; Michele Jonsson Funk; Virginia Pate; M Alan Brookhart; Amanda Patrick; Laura C Hanson; Wendy Camelo Castillo; Til Stürmer Journal: Pharmacoepidemiol Drug Saf Date: 2014-10-21 Impact factor: 2.890
Authors: Jennifer L Lund; Tzy-Mey Kuo; M Alan Brookhart; Anne-Marie Meyer; Alexandra F Dalton; Christine E Kistler; Stephanie B Wheeler; Carmen L Lewis Journal: Pharmacoepidemiol Drug Saf Date: 2019-03-19 Impact factor: 2.890